Global Metabolic Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Nov-2017
No. of pages: 500
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Global Metabolic Partnering 2010 to 2017 provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Metabolic partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Metabolic partnering agreement structure

Metabolic partnering contract documents

Top Metabolic deals by value

Most active Metabolic dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.

The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Metabolic dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Metabolic dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Metabolic deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Metabolic dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Metabolic deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2010. The chapter is organized by specific Metabolic therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Metabolic partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Metabolic technologies and products.

Report scope

Global Metabolic Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Metabolic trends and structure of deals entered into by leading companies worldwide.

Global Metabolic Partnering 2010 to 2017 includes:

Trends in Metabolic dealmaking in the biopharma industry since 2010

Analysis of Metabolic deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Metabolic deal contract documents

Comprehensive access to over 3500 Metabolic deal records

The leading Metabolic deals by value since 2010

Most active Metabolic dealmakers since 2010

The report includes deals for the following indications: Acromegaly, Addison's disease, Cirrhosis, Cushing's syndrome, Diabetes, Type 1, Type 2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders, Gynaecomastia, Inborn errors of metabolism, Phenylketonuria, Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia, Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease, Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders, Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic indications.

In Global Metabolic Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Metabolic Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 1,000 metabolic deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Key benefits

Global Metabolic Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Metabolic deal trends since 2010

Access Metabolic deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Metabolic partner companies

Comprehensive access to over 750 links to actual Metabolic deals entered into by the world's biopharma companies

Indepth review of Metabolic deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Metabolic opportunities

Uncover companies actively partnering Metabolic opportunities

Global Metabolic Partnering 2010-2017: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Metabolic dealmaking
2.1. Introduction
2.2. Metabolic partnering over the years
2.3. Metabolic partnering by deal type
2.4. Metabolic partnering by industry sector
2.5. Metabolic partnering by stage of development
2.6. Metabolic partnering by technology type
2.7. Metabolic partnering by therapeutic indication

Chapter 3 -Financial deal terms for Metabolic partnering
3.1. Introduction
3.2. Disclosed financials terms for Metabolic partnering
3.3. Metabolic partnering headline values
3.4. Metabolic deal upfront payments
3.5. Metabolic deal milestone payments
3.6. Metabolic royalty rates

Chapter 4 - Leading Metabolic deals and dealmakers
4.1. Introduction
4.2. Most active in Metabolic partnering
4.3. List of most active dealmakers in Metabolic
4.4. Top Metabolic deals by value

Chapter 5 - Metabolic contract document directory
5.1. Introduction
5.2. Metabolic partnering deals where contract document available

Chapter 6 - Metabolic dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Metabolic therapeutic target

Appendices

Appendix 1 - Directory of Metabolic deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Metabolic deals by deal type 2010 to 2017
Appendix 3 - Directory of Metabolic deals by stage of development 2010 to 2017
Appendix 4 - Directory of Metabolic deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Figures

Figure 1: Metabolic partnering since 2010
Figure 2: Metabolic partnering by deal type since 2010
Figure 3: Metabolic partnering by industry sector since 2010
Figure 4: Metabolic partnering by stage of development since 2010
Figure 5: Metabolic partnering by technology type since 2010
Figure 6: Metabolic partnering by indication since 2010
Figure 7: Metabolic deals with a headline value
Figure 8: Metabolic deals with upfront payment values
Figure 9: Metabolic deals with milestone payment
Figure 10: Metabolic deals with royalty rates
Figure 11: Active Metabolic dealmaking activity- 2010 to 2017
Figure 12: Top Metabolic deals by value since 2010
  • Global Lysosomal Storage Disease Partnering 2012-2018
    Published: 01-Feb-2018        Price: US 1495 Onwards        Pages: 100
    ""Delivery of this report will take 1-3 days after purchase."" The Global Lysosomal Storage Disease Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology type The report ......
  • Global Metabolic Partnering 2012-2018: Deal trends, players and financials
    Published: 01-Feb-2018        Price: US 2995 Onwards        Pages: 500
    ""Delivery of this report will take 1-3 days after purchase."" Global Metabolic Partnering 2012 to 2018 provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2012. Trends in Metabolic partnering deals Financial deal terms for headline, upfront and royalty by stage of development Metabolic partnering agreement structure Metabolic partnering contract doc......
  • Fabry Disease - Epidemiology Forecast to 2027
    Published: 31-Jan-2018        Price: US 3250 Onwards        Pages: 50
    DelveInsight's "Fabry Disease - Epidemiology Forecast, 2027" report provides a comprehensive analysis of the Fabry Disease epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2027 Fabry Disease Epidemiology The epidemiology section covers the h......
  • Fabry Disease - Pipeline Insight, 2018
    Published: 31-Jan-2018        Price: US 1500 Onwards        Pages: 70
    "Fabry Disease - Pipeline Insight, 2018" report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Fabry Disease development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products cov......
  • Fabry Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape
    Published: 31-Jan-2018        Price: US 1500 Onwards        Pages: 40
    Introduction DelveInsight's, "Fabry Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" report provides comprehensive insights about marketed and Phase III products for Fabry Disease . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. Global API Manufacturers of Marketed Products for Fabry Disease Cov......
  • Fabry Disease - Market Insight, Epidemiology and Market Forecast - 2027
    Published: 31-Jan-2018        Price: US 6250 Onwards        Pages: 100
    DelveInsight's "Fabry Disease - Market Insight, Epidemiology and Market Forecast - 2027" report provides a detailed analysis of the Fabry Disease epidemiology and market outlook for the 7MM. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2027 Fabry Disease Understanding and Treatment Algorithm The market report provides the overview of the Fabry Disea......
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 72
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis I - Pipeline Review, H2 2017, provides an overview of the Mucopolysaccharidosis I (Metabolic Disorders) pipeline landscape. MPS I (Mucopolysaccharidosis I) is an inherited lysosomal storage disorder caused by a deficiency of alpha-L-iduronidase, a lysosomal enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs). Symptoms ......
  • Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 53
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis II - Pipeline Review, H2 2017, provides an overview of the Mucopolysaccharidosis II (Metabolic Disorders) pipeline landscape. Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. Signs and symptoms include claw-like hands, protruding tongue, changing facial fe......
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 58
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis III - Pipeline Review, H2 2017, provides an overview of the Mucopolysaccharidosis III (Metabolic Disorders) pipeline landscape. Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is an inherited metabolic disease caused by an absence or malfunctioning of certain enzymes needed to breakdown molecules called glycosaminoglycans (GAG). Symptoms include se......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs